Gossamer Bio公布Seralutinib治疗肺动脉高压的III期Prosera研究顶线结果

美股速递
Feb 23

Gossamer Bio Inc. (股票代码:GOSS) 近日披露了其III期临床试验Prosera研究的顶线数据。该研究旨在评估候选药物Seralutinib在肺动脉高压患者中的疗效与安全性。

这项关键性研究的结果标志着公司在肺动脉高压治疗领域的重要进展。顶线数据的公布为后续研发决策提供了关键依据,也将影响该药物的上市申请策略。

肺动脉高压作为一种罕见且严重的疾病,目前仍存在未满足的临床需求。Seralutinib若最终获批,有望为患者提供新的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10